Literature DB >> 24609898

The function of EMSY in cancer development.

Jing Hou1, Ziliang Wang, Lina Yang, Xiaomao Guo, Gong Yang.   

Abstract

EMSY was first reported to bind BRCA2 and to inactivate the function of BRCA2, leading to the development of sporadic breast and ovarian cancers. The function of EMSY may also be involved in DNA damage repair, genomic instability, and chromatin remolding. Recent studies have shown that amplification of EMSY was also associated with other cancers such as prostate and pancreatic cancers and linked to tumor phenotypes and clinical outcomes. By reviewing literatures published since 2003, here, we have summarized the recent advances of EMSY in cancer development.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24609898     DOI： 10.1007/s13277-013-1584-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  32 in total

1.  The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY.

Authors:  Scott A Ezell; Christos Polytarchou; Maria Hatziapostolou; Ailan Guo; Ioannis Sanidas; Teeru Bihani; Michael J Comb; George Sourvinos; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

Authors:  Anita L Bane; Anna Marie Mulligan; Dushanthi Pinnaduwage; Frances P O'Malley; Irene L Andrulis
Journal:  Breast Cancer Res Treat       Date:  2011-02-15       Impact factor: 4.872

3.  Detailed map of a region commonly amplified at 11q13-->q14 in human breast carcinoma.

Authors:  S Bekri; J Adélaïde; S Merscher; J Grosgeorge; F Caroli-Bosc; D Perucca-Lostanlen; P M Kelley; M J Pébusque; C Theillet; D Birnbaum; P Gaudray
Journal:  Cytogenet Cell Genet       Date:  1997

4.  Identification of an aggressive prostate cancer predisposing variant at 11q13.

Authors:  Riikka Nurminen; Tiina Wahlfors; Teuvo L J Tammela; Johanna Schleutker
Journal:  Int J Cancer       Date:  2011-01-06       Impact factor: 7.396

5.  Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.

Authors:  Lindsay A Brown; Julie Irving; Robin Parker; Hanna Kim; Joshua Z Press; Teri A Longacre; Stephen Chia; Anthony Magliocco; Nikita Makretsov; Blake Gilks; Jonathan Pollack; David Huntsman
Journal:  Gynecol Oncol       Date:  2005-10-19       Impact factor: 5.482

6.  Crystal structure of the HP1-EMSY complex reveals an unusual mode of HP1 binding.

Authors:  Ying Huang; Michael P Myers; Rui-Ming Xu
Journal:  Structure       Date:  2006-04       Impact factor: 5.006

7.  Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas.

Authors:  W Arnout van Hattem; Ralph Carvalho; Ang Li; G Johan A Offerhaus; Michael Goggins
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 8.  Cyclin D1, EMS1 and 11q13 amplification in breast cancer.

Authors:  Christopher J Ormandy; Elizabeth A Musgrove; Rina Hui; Roger J Daly; Robert L Sutherland
Journal:  Breast Cancer Res Treat       Date:  2003-04       Impact factor: 4.872

9.  Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation.

Authors:  Shivani Garapaty; Chong-Feng Xu; Patrick Trojer; Muktar A Mahajan; Thomas A Neubert; Herbert H Samuels
Journal:  J Biol Chem       Date:  2009-01-08       Impact factor: 5.157

10.  Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs.

Authors:  Patrick R Benusiglio; Fabienne Lesueur; Craig Luccarini; Joan McIntosh; Robert N Luben; Paula Smith; Alison Dunning; Douglas F Easton; Bruce A J Ponder; Paul D Pharoah
Journal:  BMC Cancer       Date:  2005-07-19       Impact factor: 4.430
View more
  5 in total

1.  EMSY promoted the growth and migration of ovarian cancer cells.

Authors:  Xiaohong Zhao; Yan Zhou; Mingchao Nie; Saiqiong Xian; Huli Chen; Yingmei Wen; Linjing Zhang; Yumin Huang; Mingfa Chen; Shaosheng Wang
Journal:  Tumour Biol       Date:  2014-12-16

2.  Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.

Authors:  Agnieszka Dansonka-Mieszkowska; Lukasz M Szafron; Joanna Moes-Sosnowska; Mariusz Kulinczak; Anna Balcerak; Bozena Konopka; Magdalena Kulesza; Agnieszka Budzilowska; Martyna Lukasik; Urszula Piekarska; Iwona K Rzepecka; Joanna Parada; Renata Zub; Barbara Pienkowska-Grela; Radoslaw Madry; Jan K Siwicki; Jolanta Kupryjanczyk
Journal:  Oncotarget       Date:  2018-04-03

Review 3.  New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response.

Authors:  Klaudia Szymonowicz; Sebastian Oeck; Nathalie M Malewicz; Verena Jendrossek
Journal:  Cancers (Basel)       Date:  2018-03-18       Impact factor: 6.639

Review 4.  HRness in Breast and Ovarian Cancers.

Authors:  Elizabeth Santana Dos Santos; François Lallemand; Ambre Petitalot; Sandrine M Caputo; Etienne Rouleau
Journal:  Int J Mol Sci       Date:  2020-05-28       Impact factor: 5.923

Review 5.  A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance.

Authors:  Isabell Götting; Verena Jendrossek; Johann Matschke
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.